Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...

(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent ...

Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines PALM SPRINGS, CALIFORNIA / ACCESS Newswire / ...

Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2025 third quarter results at 8:30 a.m. CDT on Friday, October 31, 2025. Investors may access the live ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / UniDoc Health Corp.